SNTI News and Press, Senti Biosciences Inc.

2024-06-26 06:35:00 ET A Short Guide to Different Order Types With Penny Stocks Understanding the various order types can significantly enhance your strategy when trading penny stocks. Penny stocks represent an exciting opportunity for investors seeking to enter the stock market at ...

A look at the top 10 most actives in the United States GlycoMimetics Inc. (GLYC) rose 42.5% to $0.38 on volume of 73,016,681 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.16 on volume of 71,818,174 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 25.4% to $0.2431 on volume...

– SENTI-202 is a potential first-in-class Logic Gated off-the-shelf CAR-NK cell therapy – – Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 – SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Sen...

2024-05-10 07:46:46 ET More on Senti Biosciences Financial information for Senti Biosciences Read the full article on Seeking Alpha For further details see: Senti Biosciences GAAP EPS of -$0.26

– First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia (“AML”), on track for the second quarter of 2024 – SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ( ...

A look at the top 10 most actives in the United States Next.e.GO N.V. (EGOX) rose 38.0% to $0.0381 on volume of 59,468,925 shares Greenwave Technology Solutions Inc. (GWAV) rose 1.5% to $0.066 on volume of 45,683,331 shares Global Mofy Metaverse Limited (GMM) rose 68.4% to $1.5667 on volu...

– Preclinical data demonstrates the potential for improved treatment outcomes and reduced toxicity for patients with AML – – Data supports the design of Phase 1 clinical trial of SENTI-202 with patient dosing anticipated in the second quarter of 2024 – ...

– IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U.S. FDA; First patient dosing anticipated in the second quarter of 2024 – – Cash and anticipated receivables from GeneFab transaction expected to fund operations into the ...

2024-01-05 16:15:54 ET More on Senti Biosciences Senti Biosciences GAAP EPS of -$0.77 misses by $0.33 Senti stock soars 175% on Chinese development deal for cancer drug Seeking Alpha’s Quant Rating on Senti Biosciences Historical earnings data for Sent...

– Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H 2024 – – Anticipated cost savings, which includes an approximately 37% ...